



UNITED STATES PATENT AND TRADEMARK OFFICE

1
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/623,189	07/18/2003	Alexander M. DePaoli	54113.8005.US02	3581
34055	7590	07/13/2006	EXAMINER O'HARA, EILEEN B	ART UNIT PAPER NUMBER 1646

DATE MAILED: 07/13/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/623,189	DEPAOLI ET AL.
	Examiner Eileen B. O'Hara	Art Unit 1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 17 April 2006.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-32 is/are pending in the application.

4a) Of the above claim(s) 22 and 32 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-31 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-32 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 18 July 2003 is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 11/03, 1/04, 6/06.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
5) Notice of Informal Patent Application (PTO-152)
6) Other: _____.

DETAILED ACTION

1. Claims 1-32 are pending in the instant application.

Election/Restrictions

Applicant's election with traverse of Group I in the reply filed on April 17, 2006 is acknowledged. The traversal is on the ground(s) that Groups I and II are related by a genus-species relationship and a search of genus (Group I treatment with leptin) would necessarily encompass the search of the species (Group II treatment with nucleic acid encoding leptin). Also argued is that Group III (method of determining predisposition of a lipoatrophic patient to respond to leptin) and Group IV (kit) are related in such a way that examination of both would not unduly burden the Examiner. This is not found persuasive because consistent with current patent practice, a serious search burden may be established by (A) separate classification thereof: (B) a separate status in the art when they are classifiable together: (C) a different field of search:. These criteria were met in the above restriction. Groups I, II and IV are classified in different classes, and examination of Groups II and IV would also require separate search, because treatment with protein and treatment with nucleic acid are different, and search of the kit would entail a different search. However, the arguments are persuasive for Group III, and that group will also be examined with Group I.

The requirement is still deemed proper and is therefore made FINAL.

Claims 22 and 32 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claims 1-21 and 23-31 are currently under examination.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-21 and 23-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are indefinite they are incomplete method claims. The independent claims do not recite a conclusion as to what the effective dose would accomplish.

A telephone call was place with Lauren Sliger on June 29, 2006, but she could not contact clients in a timely manner.

The following publications are cited as being relevant to the state of the art of the claimed invention.

Gavrilova et al., Leptin and diabetes in lipotrophic mice, NATURE, Vo. 403, Feb. 24, 2000, pages 850-851.

Chen et al., Disappearance of body fat in normal rats induced by adenovirus-mediated leptin gene therapy, PNAS, Vo. 93, pp. 14795-14999, Dec. 1996.

Ogawa et al., Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin, DIABETES, Sept. 1999, Vol. 48, No. 9, pages 1822-1829.

Reitman et al., A-ZIP/F1 mice lacking white fat: a model for understanding lipotrophic diabetes, INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS: JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY, Nov. 2000, Vol. 24, Suppl 4, pp. S11-4.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nichol can be reached at (571) 272-0835.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://portal.uspto.gov/external/portal/pair>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free).

Eileen B. O'Hara, Ph.D.
Patent Examiner

Eileen B. O'Hara
EILEEN B. O'HARA
PRIMARY EXAMINER